Research shows how remdesivir inhibits SARS-CoV-2 replication

NewsGuard 100/100 Score

Amidst the frantic global search for a vaccine to inhibit SARS-CoV-2 or a drug to treat coronavirus 2019 (COVID-19), remdesivir has been recently approved by the U.S. FDA to treat COVID-19 patients.

The causative agent of COVID-19, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has exhibited a positive response to this nucleoside analog drug.

The virus uses an RNA-dependent RNA polymerase (RdRp) to replicate. The active form of remdesivir inhibits the RdRp and exhibits antiviral activity. However, the specific mechanism by which remdesivir inhibits the RdRp is not completely clear.

In a recent bioRxiv* preprint, a research team from Germany, Goran Kokic et al. study the molecular mechanism of remdesivir-induced stalling of RdRp - using synthetic RNA chemistry, biochemistry, and cryo-electron microscopy.

Remdesivir is a phosphoramidite prodrug that is metabolized in cells to yield an active nucleoside triphosphate (NTP) analog, referred to as remdesivir triphosphate (RTP) in this study. RdRp can use RTP as a substrate, leading to the incorporation of remdesivir monophosphate (RMP) into the growing RNA. The previous studies show how RMP is incorporated into the RNA. However, how the drug remdesivir inhibits the RdRp is explored here. Unique to coronaviruses, RdRp stalling occurs only after three more nucleotides have been added to the RNA.

In this study, the researchers investigate the following: 1) how the presence of the drug (RTP) influences the polymerase action of elongation, 2) determine the structures of RdRpRNA complexes, 3) trap the states of the RdRp complex structurally, that are relevant for understanding remdesivir-induced RdRp stalling, 4) does the RdRp stalling results from a translocation barrier.

Structural analysis of remdesivir-induced RdRp stalling. a Position of RNA scaffolds 1–3 as observed in RdRp-RNA complex structures 1–3. Template and product strands are on the top and bottom, respectively. b Cryo-EM density of RNA in the active center of structures 1–3. The active site metal ion was modelled30 and is shown as a magenta sphere. c The C1’-cyano group of the RMP ribose moiety (violet) is accommodated at position –3 (left), but would clash with the side chain of nsp12 residue serine-861 (red) at position –4 (right). Spheres indicate atomic van der Waals surfaces.
Structural analysis of remdesivir-induced RdRp stalling. a Position of RNA scaffolds 1–3 as observed in RdRp-RNA complex structures 1–3. Template and product strands are on the top and bottom, respectively. b Cryo-EM density of RNA in the active center of structures 1–3. The active site metal ion was modelled30 and is shown as a magenta sphere. c The C1’-cyano group of the RMP ribose moiety (violet) is accommodated at position –3 (left), but would clash with the side chain of nsp12 residue serine-861 (red) at position –4 (right). Spheres indicate atomic van der Waals surfaces.

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

RdRp uses RTP as a substrate, leading to the incorporation of RMP into a growing RNA product extending by three more nucleotides before it stalls. This stalling mechanism is specific to coronaviruses. For example, in the case of the Ebola virus, RdRp adds five RNA nucleotides after RMP incorporation before it stalls.

The researchers confirmed the presence of RMP in the obtained RNA oligonucleotides using denaturing HPLC and LC-MS. They also confirmed that the presence of RMP inhibits RNA extension by RdRp on minimal RNA template-product scaffolds.

Post RMP incorporation, the researchers investigated RdRp-RNA complexes - after the addition of two or three nucleotides (using cryo-EM analysis). The RdRp-RNA structures resolution is determined, also revealing the positions of RMP in the RNA product strand.

This study shows that the fourth nucleotide's addition is impaired by a barrier to further the RNA translocation. This causes retention of the RNA 3'-nucleotide in the active site of the RdRp, not allowing the next nucleoside triphosphate, thereby stalling the enzyme.

The researchers found that the translocation barrier results from the sterically impaired passage of the cyano group in RMP past the serine-861 side chain in the nsp12 (nonstructural) subunit of RdRp.

These results are consistent with biochemical studies and also previous data.

In this study, the researchers show how the remdesivir-stalled state escapes viral proofreading. The matched RNA 3'-end may escape proofreading because the viral exonuclease nsp14 preferentially recognizes a mismatched 3'-end.

However, the researchers also point out that some proofreading may occur, rendering remdesivir less efficient (the viral exonuclease can remove several nucleotides from the base-paired RNA 3'-end).

It is important to note that at high NTP concentrations, RdRp stalling was overcome, resulting in the formation of the full-length RNA; despite the presence of RMP in the RNA product. Because of these results, the researchers note that remdesivir neither acts as a chain terminator nor as an elongation block but rather triggers delayed RdRp stalling by an unknown mechanism.

This paper's mechanistic insights are critical to understanding the inhibition process of an approved antiviral drug used against SARS-CoV-2 and may further the search for compounds with improved potential in this direction to interfere with coronavirus replication.

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Journal references:

Article Revisions

  • Mar 30 2023 - The preprint preliminary research paper that this article was based upon was accepted for publication in a peer-reviewed Scientific Journal. This article was edited accordingly to include a link to the final peer-reviewed paper, now shown in the sources section.
Dr. Ramya Dwivedi

Written by

Dr. Ramya Dwivedi

Ramya has a Ph.D. in Biotechnology from the National Chemical Laboratories (CSIR-NCL), in Pune. Her work consisted of functionalizing nanoparticles with different molecules of biological interest, studying the reaction system and establishing useful applications.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Dwivedi, Ramya. (2023, March 30). Research shows how remdesivir inhibits SARS-CoV-2 replication. News-Medical. Retrieved on May 30, 2024 from https://www.news-medical.net/news/20201102/Research-shows-how-remdesivir-inhibits-SARS-CoV-2-replication.aspx.

  • MLA

    Dwivedi, Ramya. "Research shows how remdesivir inhibits SARS-CoV-2 replication". News-Medical. 30 May 2024. <https://www.news-medical.net/news/20201102/Research-shows-how-remdesivir-inhibits-SARS-CoV-2-replication.aspx>.

  • Chicago

    Dwivedi, Ramya. "Research shows how remdesivir inhibits SARS-CoV-2 replication". News-Medical. https://www.news-medical.net/news/20201102/Research-shows-how-remdesivir-inhibits-SARS-CoV-2-replication.aspx. (accessed May 30, 2024).

  • Harvard

    Dwivedi, Ramya. 2023. Research shows how remdesivir inhibits SARS-CoV-2 replication. News-Medical, viewed 30 May 2024, https://www.news-medical.net/news/20201102/Research-shows-how-remdesivir-inhibits-SARS-CoV-2-replication.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Children can boost vaccination rates by educating their grandparents